paper-plane envelope home office pencil quill pen image images camera play bullhorn connection mic file-text2 file-picture file-music file-play file-video copy folder folder-open folder-plus folder-minus folder-download folder-upload price-tag price-tags ticket phone envelop pushpin location compass map map2 clock alarm fax mobile bubble bubbles user users user-plus user-minus user-check quotes-left quotes-right search pie-chart stats-dots stats-bars airplane cloud-download cloud-upload earth link flag eye eye-blocked arrow-up-left arrow-up arrow-up-right arrow-right arrow-down-right arrow-down arrow-down-left arrow-left2 share amazon google-plus google-drive facebook instagram twitter rss youtube flickr dropbox linkedin file-pdf file-openoffice file-word file-excel

UCL Mechanical Engineering
Faculty of Engineering Sciences


In vivo preclinical stage started for the Triskele UCL Transcatheter Aortic Valve

The novel transcatheter aortic valve developed at UCL, was for the first time implanted in an ovine model (about 50 kg) on the 29th of May 2013, by Mike Mullen and John Yap (UCLH Heart Hospital), at IMM Recherche, Paris.Triskele Logo The valve was collapsed in the delivery system and successfully implanted off-pump via brachiocephalic approach in orthotopic position, using continuous ultrasonic and fluoroscopic guidance.

Dr Mullen successfully implanted and extracted three valves of different sizes (23 mm, 26 mm and 29 mm). Each valve was retrieved into the catheter and repositioned, after assessing their optimal positioning and hemodynamic performance.  No interference of coronary blood flow was observed for the two smallest sizes, more suitable for the animal anatomy, and good acute valve function with no significant regurgitation was confirmed for all devices.

The first preclinical in vivo trial has confirmed the unique features of the device, developed from a multidisciplinary collaboration between the UCL Department of Mechanical Engineering (Dr G Burriesci – Project Leader – and his team), the UCL Centre for Nanotechnology & Regenerative Medicine (Prof A Seifalian’s group) and The Heart Hospital UCLH (Dr M Mullen and Mr J Yap), with the support of the Wellcome Trust.

Last modified on

Back to top